Received Jun 16, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | 2553X | — |
Twinrix early third dose; This non-serious case was reported by a other health professional via call center representative and described the occurrence of drug dose administration interval too short in a 68-year-old female patient who received HAB (Twinrix) (batch number 2553X, expiry date 25-SEP-2026) for prophylaxis. Previously administered products included Twinrix (first dose taken on 27 Dec 2024) and Twinrix (second dose taken on 28 Jan 2025). On 20-MAR-2025, the patient received the 3rd dose of Twinrix. On 20-MAR-2025, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too short (Verbatim: Twinrix early third dose). The outcome of the drug dose administration interval too short was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 11-JUN-2025 The patient that received the third dose of Twinrix on 20 Mar 2025, 3 months earlier than recommended which led to Drug dose administration interval too short. First and second dose were given following the proper schedule on 27 Dec 2024 and 28 Jan 2025.